{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:19:00Z","timestamp":1790813940736,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.mayocp.2015.07.005","type":"journal-article","created":{"date-parts":[[2015,11,2]],"date-time":"2015-11-02T07:23:56Z","timestamp":1446449036000},"page":"1574-1583","source":"Crossref","is-referenced-by-count":162,"title":["Hodgkin Lymphoma: Diagnosis and Treatment"],"prefix":"10.1016","volume":"90","author":[{"given":"Stephen M.","family":"Ansell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mayocp.2015.07.005_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.mayocp.2015.07.005_bib2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0950-3536(96)80018-7","article-title":"The epidemiology of Hodgkin's disease","volume":"9","author":"Glaser","year":"1996","journal-title":"Baillieres Clin Haematol"},{"issue":"5","key":"10.1016\/j.mayocp.2015.07.005_bib3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJM197702032960504","article-title":"Hodgkin's disease in siblings","volume":"296","author":"Grufferman","year":"1977","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2015.07.005_bib4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/07357909209032768","article-title":"Genetics of Hodgkin's and non-Hodgkin's lymphoma: a review","volume":"10","author":"Lynch","year":"1992","journal-title":"Cancer Invest"},{"issue":"7","key":"10.1016\/j.mayocp.2015.07.005_bib5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1056\/NEJM199502163320701","article-title":"Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease","volume":"332","author":"Mack","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2015.07.005_bib6","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1086\/302608","article-title":"Pseudoautosomal linkage of Hodgkin disease","volume":"65","author":"Horwitz","year":"1999","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.mayocp.2015.07.005_bib7","first-page":"86","article-title":"Epstein-Barr viral DNA in tissues of Hodgkin's disease","volume":"129","author":"Weiss","year":"1987","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.mayocp.2015.07.005_bib8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/(SICI)1097-0215(19991112)83:4<481::AID-IJC8>3.0.CO;2-5","article-title":"Advances in the epidemiology of HIV-associated non-Hodgkin's lymphoma and other lymphoid neoplasms","volume":"83","author":"Franceschi","year":"1999","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.mayocp.2015.07.005_bib9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/oxfordjournals.annonc.a058617","article-title":"Hodgkin's disease during HIV1 infection: the French registry experience","volume":"4","author":"Andrieu","year":"1993","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.mayocp.2015.07.005_bib10","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1200\/JCO.1995.13.7.1758","article-title":"Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors","volume":"13","author":"Tirelli","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2015.07.005_bib11","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1054\/bjoc.1999.1049","article-title":"Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents","volume":"82","author":"Alexander","year":"2000","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.mayocp.2015.07.005_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.mayocp.2015.07.005_bib13","series-title":"World Health Organization (WHO) Classification of Tumours: Pathology & Genetics; Tumours of Haematopoietic and Lymphoid Tissues","first-page":"237","article-title":"Hodgkin Lymphoma","author":"Stein","year":"2001"},{"key":"10.1016\/j.mayocp.2015.07.005_bib14","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"2","key":"10.1016\/j.mayocp.2015.07.005_bib15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1054\/blre.2002.0190","article-title":"Hodgkin's disease","volume":"16","author":"Ekstrand","year":"2002","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.mayocp.2015.07.005_bib16","first-page":"211","article-title":"Hodgkin's disease, lymphocyte predominance type, nodular\u2014further evidence for a B cell derivation: L & H variants of Reed-Sternberg cells express L26, a pan B cell marker","volume":"133","author":"Pinkus","year":"1988","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.mayocp.2015.07.005_bib17","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","article-title":"Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease","volume":"17","author":"Diehl","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2015.07.005_bib18","first-page":"266","article-title":"Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease","volume":"86","author":"Jerusalem","year":"2001","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.mayocp.2015.07.005_bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood.V73.1.47.47","article-title":"Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease: the EORTC Lymphoma Group controlled clinical trials; 1964-1987","volume":"73","author":"Tubiana","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2015.07.005_bib20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1182\/asheducation-2003.1.225","article-title":"Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease","author":"Diehl","year":"2003","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"21","key":"10.1016\/j.mayocp.2015.07.005_bib21","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"International Prognostic Factors Project on Advanced Hodgkin's Disease. A prognostic score for advanced Hodgkin's disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2015.07.005_bib22","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/blood.V94.2.429","article-title":"Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging","volume":"94","author":"Jerusalem","year":"1999","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mayocp.2015.07.005_bib23","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1023\/A:1008327127033","article-title":"The role of positron emission tomography (PET) in the management of lymphoma patients","volume":"10","author":"Zinzani","year":"1999","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2015.07.005_bib24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","author":"Hutchings","year":"2006","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.mayocp.2015.07.005_bib25","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.mayocp.2015.07.005_bib26","first-page":"2101","article-title":"Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy","volume":"5","author":"Brusamolino","year":"1994","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2015.07.005_bib27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1111961","article-title":"ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma","volume":"366","author":"Meyer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.mayocp.2015.07.005_bib28","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.mayocp.2015.07.005_bib29","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.mayocp.2015.07.005_bib30","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.mayocp.2015.07.005_bib31","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"Engert","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"10.1016\/j.mayocp.2015.07.005_bib32","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.mayocp.2015.07.005_bib33","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial","volume":"30","author":"von Tresckow","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.mayocp.2015.07.005_bib34","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00259-010-1490-5","article-title":"Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma","volume":"37","author":"Barrington","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"21","key":"10.1016\/j.mayocp.2015.07.005_bib35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/blood.V120.21.549.549","article-title":"Interim analysis of the randomized Eortc\/Lysa\/Fil Intergroup H10 trial on early PET-scan driven treatment adaptation in stage I\/II Hodgkin lymphoma [abstract]","volume":"120","author":"Andr\u00e9","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2015.07.005_bib36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/JCO.1992.10.2.210","article-title":"Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure","volume":"10","author":"Longo","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.mayocp.2015.07.005_bib37","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2015.07.005_bib38","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1200\/JCO.1996.14.5.1421","article-title":"Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results","volume":"14","author":"Viviani","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2015.07.005_bib39","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO.1997.15.4.1638","volume":"15","author":"Connors","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2015.07.005_bib40","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","article-title":"Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial","volume":"21","author":"Duggan","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2015.07.005_bib41","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.1995.13.5.1080","article-title":"Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report","volume":"13","author":"Bartlett","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2015.07.005_bib42","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2000.18.5.972","article-title":"Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492","volume":"18","author":"Horning","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"32","key":"10.1016\/j.mayocp.2015.07.005_bib43","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1200\/JCO.2010.30.9799","article-title":"Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP\/EBV\/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi","volume":"29","author":"Chisesi","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"32","key":"10.1016\/j.mayocp.2015.07.005_bib44","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2009.23.3239","article-title":"Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244","volume":"27","author":"Hoskin","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.mayocp.2015.07.005_bib45","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood.V116.21.415.415","article-title":"A\u00a0randomized phase III trial of ABVD vs. Stanford V\u00a0+\/\u2013 radiation therapy in locally extensive and advanced stage Hodgkin's lymphoma: an intergroup study coordinated by the Eastern Cooperatve Oncology Group (E2496) [abstract]","volume":"116","author":"Gordon","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2015.07.005_bib46","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1023\/A:1008294312741","article-title":"BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease","volume":"8","author":"Diehl","year":"1997","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.mayocp.2015.07.005_bib47","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease [published correction appears in N Engl J Med. 2005;353(7):744]","volume":"348","author":"Diehl","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"27","key":"10.1016\/j.mayocp.2015.07.005_bib48","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2015.07.005_bib49","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial","volume":"27","author":"Federico","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2015.07.005_bib50","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9828","key":"10.1016\/j.mayocp.2015.07.005_bib51","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.mayocp.2015.07.005_bib52","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(13)70341-3","article-title":"Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis","volume":"14","author":"Skoetz","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2015.07.005_bib53","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1056\/NEJMe1104576","article-title":"Hodgkin's lymphoma\u2014the great teacher [editorial]","volume":"365","author":"Connors","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.mayocp.2015.07.005_bib54","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.mayocp.2015.07.005_bib55","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1182\/blood.V122.21.4344.4344","article-title":"Targeted BEACOPP variants in patients with newly diagnosed advanced stage classical Hodgkin lymphoma: interim results of a randomized phase II study [abstract]","volume":"122","author":"Borchmann","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2015.07.005_bib56","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","article-title":"Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial","volume":"101","author":"Ekstrand","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2015.07.005_bib57","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.V101.2.420","article-title":"German Hodgkin Lymphoma Study Group (GHSG). Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group","volume":"101","author":"Rehwald","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2015.07.005_bib58","series-title":"Textbook of Medical Oncology","first-page":"461","article-title":"Hodgkin's disease","author":"Horning","year":"2000"},{"key":"10.1016\/j.mayocp.2015.07.005_bib59","series-title":"Principles and Practice of Oncology","first-page":"2339","article-title":"Hodgkin's disease","author":"Diehl","year":"2001"},{"issue":"3","key":"10.1016\/j.mayocp.2015.07.005_bib60","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1023\/A:1008283909959","article-title":"Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM)","volume":"9","author":"Josting","year":"1998","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2015.07.005_bib61","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1200\/JCO.1999.17.2.534","article-title":"Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry","volume":"17","author":"Lazarus","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2015.07.005_bib62","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.bmt.1700838","article-title":"Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry","volume":"20","author":"Brice","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"8852","key":"10.1016\/j.mayocp.2015.07.005_bib63","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"issue":"9323","key":"10.1016\/j.mayocp.2015.07.005_bib64","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mayocp.2015.07.005_bib65","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JCO.1997.15.1.18","article-title":"Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies","volume":"15","author":"Kusnierz-Glaz","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.mayocp.2015.07.005_bib66","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/sj.bmt.1704214","article-title":"Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma","volume":"32","author":"Kewalramani","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"5-6","key":"10.1016\/j.mayocp.2015.07.005_bib67","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/10428199609054778","article-title":"Vinorelbine: a new promising drug in Hodgkin's disease","volume":"22","author":"Devizzi","year":"1996","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"10.1016\/j.mayocp.2015.07.005_bib68","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2000.18.13.2615","article-title":"Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study","volume":"18","author":"Santoro","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.mayocp.2015.07.005_bib69","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2015.07.005_bib70","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/j.seminoncol.2003.10.018","article-title":"Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin's disease: indications and results","volume":"31","author":"Schmitz","year":"2004","journal-title":"Semin Oncol"},{"issue":"19","key":"10.1016\/j.mayocp.2015.07.005_bib71","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.mayocp.2015.07.005_bib72","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.mayocp.2015.07.005_bib73","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","article-title":"Panobinostat in patients with relapsed\/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study","volume":"30","author":"Younes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.mayocp.2015.07.005_bib74","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","article-title":"A\u00a0phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma","volume":"118","author":"Fehniger","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.mayocp.2015.07.005_bib75","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1182\/blood.V120.21.2740.2740","article-title":"Everolimus for relapsed\/refractory classical Hodgkin lymphoma: multicenter, open-label, single-arm, phase 2 study [abstract]","volume":"120","author":"Johnston","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2015.07.005_bib76","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619615005509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619615005509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T15:08:36Z","timestamp":1599750516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619615005509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":76,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0025619615005509"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2015.07.005","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}